Active, not recruitingPHASE1, PHASE2NCT06549257

Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant

Studying Malaria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Oxford
Principal Investigator
Paola Cicconi, PhD
University of Oxford
Intervention
Pfs25-IMX313, Pfs48/45(biological)
Enrollment
56 target
Eligibility
5-45 years · All sexes
Timeline
20252026

Study locations (1)

Collaborators

European and Developing Countries Clinical Trials Partnership (EDCTP)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06549257 on ClinicalTrials.gov

Other trials for Malaria

Additional recruiting or active studies for the same condition.

See all trials for Malaria

← Back to all trials